IgD-λ+λ双克隆多发性骨髓瘤2例报道
Mutiple Myeloma with Double Clones of IgD-λ+λ:Two Cases Report
-
摘要: 目的 提高对IgD-λ+λ双克隆型多发性骨髓瘤的认识和诊治水平, 避免漏诊和误诊.方法 回顾分析昆明医科大学第二附属医院2014年1月至2016年11月收治的2例IgD-λ+λ双克隆型多发性骨髓瘤并复习相关文献.结果 研究观察期间昆明医科大学第二附属医院收治初诊MM患者共79例, 本组2例患者, 1例男性, 45岁;1例女性, 51岁, 分型均为IgD-λ+λ, 分期均为Ⅲ期B组.临床表现有贫血、骨痛、肾功能不全、消瘦乏力.血钙、LDH均有不同程度升高, 免疫球蛋白IgG、IgA、IgM均出现降低, 均经免疫固定电泳发现2条单克隆M蛋白区带, 明确诊断为IgD-λ+λ双克隆型MM.其中1例接受4个疗程VADT方案, 后疗效评估PR, 随访目前仍存活;另外1例因经济原因未接受治疗出院.结论 IgD-λ+λ双克隆型MM临床罕见, 对该疾病临床特点、实验室特点、诊断、治疗转归及预后方面目前尚缺乏较为深刻一致的认识, 尚需更多临床病例总结分析.Abstract: Objective To improve the recognition level, diagnostic therapeutic level of IgD-λ+λ type mutiple myeloma, and also reduce the rate of missed diagnosis and misdiagnosis.Methods We retrospectively reported and analyzed two cases double clones of IgD-λ+λ type multiple myelomadiagnosed in our hospital from January to November in 2014.Results There were 79 cases of multiple myeloma patients during observing time.Two patients in this study, male one was 45 years old while the female one 51 years old when they first came to be diagnosed.Both of them were diagnosed of double clones of IgD-λ+λ stage Ⅲ B group.Clinical manifestation included anemia, ostealgia, renal failure, thin and weak.Serum calcium and LDH levels were increased in different degree.The levels of immune globulin IgG, IgA, IgM were decreased and immunofixation electrophresis showed two monoclonal zone.Then they were both diagnosed IgD-λ+λ type mutiple myelom.One patient reached PR after four courses VADT chemotherapy and now is still alive.Another one didn't accept any treatment because of poverty.Conclusions The double clones IgD-λ+λ type multiple myelomais is a kind of rare plasma cell disorder, sicientists now haven't reached a profond understanding about its clinical features, laboratory features diagnositic criteria and therapeutic prognosis.More clinical cases are needed to summarize and analyze in the future study.
-
Key words:
- Double clones /
- Multiple myeloma /
- IgD-λ+λ /
- Immunofixation
-
[1] [1]DASH NR, MOHANTY B.Multiple myeloma:a case of atypical presentation on protein electrophoresis[J].Indian J Clin Biochem, 2012, 27 (1) :100-102.[1]DASH NR, MOHANTY B.Multiple myeloma:a case of atypical presentation on protein electrophoresis[J].Indian J Clin Biochem, 2012, 27 (1) :100-102. [2] [2]KIM M K, SUH C, LEE D H, et al.Immunoglobulin D mutiple myeloma:response to therapy, survival, and prognostic factors in 75 patients[J].Ann Oncol, 2011, 22 (2) :411-416.[2]KIM M K, SUH C, LEE D H, et al.Immunoglobulin D mutiple myeloma:response to therapy, survival, and prognostic factors in 75 patients[J].Ann Oncol, 2011, 22 (2) :411-416. [3]郎海波, 王平, 陈婧, 等.克罗恩氏病并IgA-λ/λ双克隆型多发性骨髓瘤1例报道并文献分析[J].临床消化病杂志, 2014, 26 (4) :240-241.[3]郎海波, 王平, 陈婧, 等.克罗恩氏病并IgA-λ/λ双克隆型多发性骨髓瘤1例报道并文献分析[J].临床消化病杂志, 2014, 26 (4) :240-241. [4] [4]VIOLETA RABRENOVIU, ZORAN MIJUSKOVIU, SLOBODAN MARJANOVIU, et al.Kidney failure as an unusual initial presentation of biclonal gammopathy (IgD multiple myeloma associated with light chaindisease) -A case report[J].Vojnosanit Pregl, 2015, 72 (2) :196-199.[4]VIOLETA RABRENOVIU, ZORAN MIJUSKOVIU, SLOBODAN MARJANOVIU, et al.Kidney failure as an unusual initial presentation of biclonal gammopathy (IgD multiple myeloma associated with light chaindisease) -A case report[J].Vojnosanit Pregl, 2015, 72 (2) :196-199. [5]张之南, 沈悌, 主编.血液病诊断及疗效标准[M].北京:科学出版社, 2007:116-134.[5]张之南, 沈悌, 主编.血液病诊断及疗效标准[M].北京:科学出版社, 2007:116-134. [6] [6]GREIPP P R, MIGUEL J S, DURIE B G M, et al.International staging system for multiple myeloma[J].Journal of clinical oncology, 2005, 23 (15) :3412-3420.[6]GREIPP P R, MIGUEL J S, DURIE B G M, et al.International staging system for multiple myeloma[J].Journal of clinical oncology, 2005, 23 (15) :3412-3420. [7] [7]HEBER E C, RENNKE H G, LAUBACH J P, et al.Kidney disease and multiple myeloma[J].Clin J A m Soc Nephrol, 2013, 8 (11) :2007-2017.[7]HEBER E C, RENNKE H G, LAUBACH J P, et al.Kidney disease and multiple myeloma[J].Clin J A m Soc Nephrol, 2013, 8 (11) :2007-2017. [8] [8]SHABNAM SHALAPOUR, MICHAEL KARIN.Immunity, inflammati-on, and cancer:an eternal fight between good and evil[J].J Clin Invest, 2015, 125 (9) :3347-3355.[8]SHABNAM SHALAPOUR, MICHAEL KARIN.Immunity, inflammati-on, and cancer:an eternal fight between good and evil[J].J Clin Invest, 2015, 125 (9) :3347-3355. [9]王慧娟, 李燕郴, 胡影, 等.双克隆型多发性骨髓瘤五例[J].白血病.淋巴瘤, 2010, 12 (19) :748-749.[9]王慧娟, 李燕郴, 胡影, 等.双克隆型多发性骨髓瘤五例[J].白血病.淋巴瘤, 2010, 12 (19) :748-749. [10] 郎海波, 王平, 陈婧, 等.克罗恩氏并IgA-λ+λ双克隆型多发性骨髓瘤1例报道并文献分析[J].临床消化病杂志.2014, 26 (4) :240-241.[10]郎海波, 王平, 陈婧, 等.克罗恩氏并IgA-λ+λ双克隆型多发性骨髓瘤1例报道并文献分析[J].临床消化病杂志.2014, 26 (4) :240-241. [11] [11]PALUMBO A, ANDERSON K.Multiple myeloma[J].N Engl J Med, 2011, 364 (11) :1046-1060.[11]PALUMBO A, ANDERSON K.Multiple myeloma[J].N Engl J Med, 2011, 364 (11) :1046-1060. [12] [12]GENTRY M, PETTENATI M, PANG C S.Biclonal light chain gammopathy with aberrant CD33 expression in secondary plasma cell leukemia[J].Int J Clin Exp Pathol, 2013, 6 (10) :2224-2229.[12]GENTRY M, PETTENATI M, PANG C S.Biclonal light chain gammopathy with aberrant CD33 expression in secondary plasma cell leukemia[J].Int J Clin Exp Pathol, 2013, 6 (10) :2224-2229. [13]陈海飞, 傅卫军, 王东星, 等.40例多发性骨髓瘤伴髓外病变患者的临床特征分析[J].中华血液学杂志, 2007, 28 (10) :655-658.[13]陈海飞, 傅卫军, 王东星, 等.40例多发性骨髓瘤伴髓外病变患者的临床特征分析[J].中华血液学杂志, 2007, 28 (10) :655-658. [14]徐岚, 王焰, 吴文, 等.多发性骨髓瘤182例临床分析[J].中华医学杂志, 2010, 90 (14) :972-977.[14]徐岚, 王焰, 吴文, 等.多发性骨髓瘤182例临床分析[J].中华医学杂志, 2010, 90 (14) :972-977. [15] [15]LONIAL S, ANDERSON K C.Association of response endpoints wiith survival outcomes in multiple myeloma[J].Leukemia, 2014, 28 (2) :258-268.[15]LONIAL S, ANDERSON K C.Association of response endpoints wiith survival outcomes in multiple myeloma[J].Leukemia, 2014, 28 (2) :258-268. [16]颜绵生, 梁鉴波, 王松子, 等.56例IgD型多发性骨髓瘤的分型研究[J].中国医药指南, 2013, 11 (20) :433-434.[16]颜绵生, 梁鉴波, 王松子, 等.56例IgD型多发性骨髓瘤的分型研究[J].中国医药指南, 2013, 11 (20) :433-434. [17] [17]Thorsten Derlin, Peter Bannas.Imaging of multiple myeloma:Current concepts[J].World J Orthop, 2014, 5 (3) :272-282.[17]Thorsten Derlin, Peter Bannas.Imaging of multiple myeloma:Current concepts[J].World J Orthop, 2014, 5 (3) :272-282. [18] [18]NI I B, CHING N C, MENG C K, et al.Translocation t (11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients:a Malaysian study[J].Hematol Rep, 2012, 4 (3) ;e19.[18]NI I B, CHING N C, MENG C K, et al.Translocation t (11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients:a Malaysian study[J].Hematol Rep, 2012, 4 (3) ;e19. [19] [19]ANGELA BAKER, ESTEBAN BRAGGIO, SUSANNA JACOBUS, et al.Uncovering the biology of multiple myeloma among African Americans:A comprehensive genomics approach[J].Blood, 2013, 121 (16) :3147-3152.[19]ANGELA BAKER, ESTEBAN BRAGGIO, SUSANNA JACOBUS, et al.Uncovering the biology of multiple myeloma among African Americans:A comprehensive genomics approach[J].Blood, 2013, 121 (16) :3147-3152. [20] [20]SHIN H J, KIM K, LEE J J, et al.The t (11;14) (q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma[J].Clin Lymphoma Myeloma Leuk, 2015, 15 (4) :227-235.[20]SHIN H J, KIM K, LEE J J, et al.The t (11;14) (q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma[J].Clin Lymphoma Myeloma Leuk, 2015, 15 (4) :227-235. [21] [21]MORIE A GERTZ, DAVID DINGLI.How we manage autologous stem cell transplantation for patients with multiple myeloma[J].Blood, 2014, 124 (6) :882-890.[21]MORIE A GERTZ, DAVID DINGLI.How we manage autologous stem cell transplantation for patients with multiple myeloma[J].Blood, 2014, 124 (6) :882-890.
点击查看大图
计量
- 文章访问数: 1829
- HTML全文浏览量: 654
- PDF下载量: 95
- 被引次数: 0